Kodiak Sciences Inc. (Nasdaq: KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR").

Usha (name changed), 62, was experiencing sudden and painless loss of vision in the right eye for one day when she turned up ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

According to Future Market Insight, the global diabetic retinopathy market is likely to reach USD 15.50 billion by 2033, registering a CAGR of 5.8%. This is a significant rise from the estimated value ...

Kodiak reports completing patient enrollment in its late-stage study evaluating tarcocimab for diabetic retinopathy.

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and ...

Diabetes can affect many parts of the body, including the eyes. Routine eye exams can help identify the early stages of eye ...

The rate of any diabetes-related retinal diseases increased from 10.8% in 2014 to 20.8% in 2021, the findings have reported.

Dr. Amit Gupta, MD, FACS, Ophthalmologist, talks about what to expect after having laser eye treatment for diabetic retinopathy.

GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study sugges ...

NY Retina, a newly launched ophthalmology practice, is set to open March 20 in a newly purchased medical office building in ...